Canaccord Genuity Assumes Coverage on Optimer Pharmaceuticals (OPTR) at Buy; Near Term Growth Driven by Unmet Need

Article Stock Quotes (1) Comments (0)

Canaccord Genuity assumes coverage on Optimer Pharmaceuticals (NASDAQ: OPTR) with a Buy. PT $21.00.

Analyst, Ritu Baral, said, "...expectation of steady revenue growth driven by unmet need and Dificid’s superior efficacy in Clostridium difficile-associated diarrhea (CDAD). We feel there is still unmet need given the relapse rates associated with other therapies, the rising incidence of CDAD, and the growing severity of the disease. Further, we think the pharmaco-economics of Dificid treatment will drive uptake over time, despite premium pricing. Our $21 target is based on a DCF of Dificid/Dificlir sales and royalties."

For an analyst ratings summary and ratings history on Optimer Pharmaceuticals click here. For more ratings news on Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $15.03 yesterday, with a 52 week range of $6.81-$17.95.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold
• Topeka Capital Starts CEVA Inc. (CEVA) at Buy
• Guggenheim Starts Biota Pharmaceuticals (BOTA) at Buy

Create E-mail Alert Related Categories

New Coverage

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?